盐酸替罗非班对急性冠状动脉综合征患者的疗效观察

选择2006年12月至2008年6月入院的急性冠状动脉综合征（ACS）患者159例，分为经皮冠状动脉介入治疗（PCI）组和内科保守治疗组，两组患者再随机分为替罗非班治疗亚组和对照亚组，比较各亚组间48h心电图改变、住院期间及随访30d主要心血管事件的发生率及出血的发生率等。结果示两组中替罗非班亚组心电图均明显改善（P〈0．01）；内科保守治疗组中替罗非班亚组随访30d主要心血管事件发生率较对照亚组显著降低（P〈0．05），出血发生率两组差异无统计学意义（P〉0．05）。提示ACS患者使用替罗非班能进一步减少心肌缺血事件，且安全性好。

Safety and efficacy of Tirofiban in patients with acute coronary syndrome

A total of 159 patients with acute coronary syndrome(ACS)were enrolled from December 2006 to June 2008 and divided into the percutaneous coronary intervention(PCI)group and the internal medicine treatment group.The participants in the two groups were further assigned to the Tirofiban or the placebo control group.The change in electrocardiograph within 48 hours,major adverse cardiac events (MACE)during hospital stay and 30 days' follow-up,and bleeding were compared between the sub-groups.As a result,in comparison with the placebo control groups,the Tirofiban sub-groups showed significant improvement in electrocardiography(P＜0.01).In the internal medicine treatment group,the rate of MACE during 30 days' follow-up was significantly decreased in patients treated with Tirofiban(P＜0.05),although no significant difference in bleeding rate was found.Our data suggest that Tirofiban may be safe and effective in the treatment of ACS.